AKTX (Akari Therapeutics plc ADR (0.01 USD))
Insider Trading Activity
Every open-market purchase and sale reported by AKTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Kameel D. Farag | Interim CFO | A | — | — |
| 2026-08-05 | Kameel D. Farag | Interim CFO | A | — | — |
| 2026-07-17 | Samir Rashmikant Patel | Director | M | — | — |
| 2026-06-25 | Abizer Gaslightwala | CEO | A | — | — |
| 2026-06-25 | Kameel D. Farag | Interim CFO | A | — | — |
| 2026-03-16 | James R Neal | Director | Buy | — | — |
| 2025-12-18 | Samir Rashmikant Patel | Director | Buy | — | — |
| 2025-12-18 | Raymond Prudo-Chlebosz | Director | Buy | — | — |
| 2025-12-18 | Sandip I Patel | Director | Buy | — | — |
| 2025-12-18 | Abizer Gaslightwala | CEO | Buy | — | — |
| 2025-12-18 | Hoyoung Huh | Director | Buy | — | — |
| 2025-12-18 | Robert B Bazemore | Director | Buy | — | — |
| 2025-12-18 | Kameel D. Farag | Interim CFO | Buy | — | — |
| 2025-11-04 | Kameel D. Farag | Interim CFO | A | — | — |
| 2025-10-24 | Kameel D. Farag | Interim CFO | A | — | — |
| 2025-08-29 | Abizer Gaslightwala | CEO | Buy | — | — |
| 2025-06-25 | Abizer Gaslightwala | President & CEO | Buy | — | — |
| 2025-06-24 | Abizer Gaslightwala | President & CEO | Buy | — | — |
| 2025-06-20 | Abizer Gaslightwala | President & CEO | Buy | — | — |
| 2025-06-16 | Abizer Gaslightwala | CEO | A | — | — |
| 2025-06-12 | Abizer Gaslightwala | CEO | A | — | — |
| 2025-04-29 | Sandip I Patel | Director | A | — | — |
| 2025-03-24 | Abizer Gaslightwala | Director | A | — | — |
| 2025-03-24 | Raymond Prudo-Chlebosz | Director | A | — | — |
| 2025-03-24 | Torsten Hombeck | CFO | A | — | — |
| 2025-03-24 | Samir Rashmikant Patel | Director | A | — | — |
| 2025-03-24 | Robert B Bazemore | Director | A | — | — |
| 2025-03-24 | Sandip I Patel | Director | A | — | — |
| 2025-03-24 | Hoyoung Huh | Director | A | — | — |
| 2025-03-24 | James R Neal | Director | A | — | — |
| 2025-03-10 | James R Neal | Director | A | — | — |
| 2025-03-10 | Robert B Bazemore | Director | A | — | — |
| 2025-03-10 | Samir Rashmikant Patel | Director | A | — | — |
| 2025-03-10 | Hoyoung Huh | Director | A | — | — |
| 2025-03-10 | Raymond Prudo-Chlebosz | Director | A | — | — |
| 2025-03-10 | Abizer Gaslightwala | Director | A | — | — |
| 2025-02-07 | Abizer Gaslightwala | Director | A | — | — |
| 2025-01-13 | Torsten Hombeck | CFO | A | — | — |
| 2025-01-13 | Abizer Gaslightwala | Director | A | — | — |
| 2025-01-10 | James R Neal | Director | A | — | — |
| 2025-01-07 | Abizer Gaslightwala | Director | A | — | — |
| 2025-01-07 | Samir Rashmikant Patel | Director | A | — | — |
| 2024-12-30 | Abizer Gaslightwala | Director | A | — | — |
| 2024-12-30 | Samir Rashmikant Patel | Director | A | — | — |
| 2024-12-27 | Abizer Gaslightwala | Director | A | — | — |
| 2024-12-27 | Samir Rashmikant Patel | Director | A | — | — |
| 2024-12-26 | James R Neal | Director | A | — | — |
| 2024-12-26 | Samir Rashmikant Patel | Director | A | — | — |
| 2024-12-26 | Samir Rashmikant Patel | Director | A | — | — |
| 2024-12-03 | Samir Rashmikant Patel | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 25,450,695 | — |
| — | Interim CFO | 3,961,848 | — |
| — | Director | 120,132 | — |
| — | Director | 80,542 | — |
| — | Director | 72,135 | — |
| — | Interim CFO | 23,309 | — |
| — | Director | 12,568 | — |
| — | CEO | 7,389 | — |
| — | Director | 1,320 | — |
| — | Director | 1,116 | — |
| — | Director | 907 | — |
| — | CFO | 5 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AKTX quote page; the site-wide leaderboard is on the insider transactions hub.